Eloxx Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELOX research report →
Range $32 – $40
Price Chart
About the company
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials.
- CEO
- Sumit Aggarwal
- IPO
- 2026
- Employees
- 10
- HQ
- Watertown, MA, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a damaged multi-month downtrend, trading below both the 50-day and 200-day moving averages. It has rebounded from the 52-week low of $8.20, but remains far below the 52-week high of $23.40, so the regime is a deep reset rather than a confirmed reversal.
Street sentiment is constructive, with a Buy consensus and a $36.67 median target versus a $10.65 last close. Recent calls have been mixed but still positive: Guggenheim trimmed its target to $40 from $43, while Leerink initiated at Outperform and another firm started at Buy, keeping the broader tone favorable.
The next earnings date is 2027-02-12, and the latest quarter showed an EPS loss of $0.49. Forward estimates stay negative, with 2027 EPS at -$2.2075 and 2027 revenue modeled at $173.813 million, so shareholders should watch cash burn and whether clinical progress supports the valuation.
No discretionary insider buying or selling stands out. The activity is dominated by award-type grants to directors and the CEO, plus ownership-related transfers, which read as compensation and administrative flows rather than a conviction signal.
The balance sheet is still net cash positive, with $4.791 million in cash against $1.0 million of debt and $3.791 million of net cash. Profitability remains weak, with 2025 operating cash flow of -$6.327 million and free cash flow at $0, so the setup depends on financing discipline and pipeline execution.
ELOX sits in the speculative end of biotech, where clinical optionality matters more than current earnings power. Versus the sector, it screens as inexpensive on headline earnings metrics, but that reflects a business still posting losses and limited operating scale.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $36.73M
- P/E
- -1.43
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 2.96
- EV/EBITDA
- 0.50
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.91%
- ROIC
- -29.83%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-6,438,000
- Net Income
- $-5,995,000-90.7%
- EPS
- $-5.34+42.2%
- OCF Growth
- -34.2%
- FCF Growth
- +100.0%
- 52W High
- $23.40
- 52W Low
- $8.20
- 50D MA
- $14.02
- 200D MA
- $14.39
- Beta
- -9.95
- RSI (14)
- 33
- Avg Volume
- 28.48K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Eloxx ended 2020 with $24.7 million in cash, a narrower annual loss, and said its top priority remains first-half 2021 Phase II cystic fibrosis data for ELX-02.· March 11, 2021
- Top-line Phase II CF data for ELX-02 remains on track for the first half of 2021.
- Independent safety review committees allowed dose escalation to the fourth and highest dose level; no drug-related serious adverse events were reported to date.
- The company expanded its CF trial footprint with new sites in Australia and Canada and said Cystic Fibrosis Foundation support has broadened.
- 2020 losses narrowed year over year as R&D and G&A spending fell sharply.
- Management said it is looking for Orkambi-/Symdeko-like sweat chloride reductions as a clinically meaningful CF readout.
Eloxx reported fourth-quarter 2020 net loss of $6.1 million, or $0.15 per share, versus a net loss of $11.6 million, or $0.29 per share in the same quarter of 2019. Fourth-quarter R&D expense was $2.6 million versus $5.9 million a year ago, and G&A expense was $3.1 million versus $5.6 million. For the full year 2020, net loss was $34.6 million, or $0.86 per share, compared with a net loss of $50.9 million, or $1.34 per share in 2019. Full-year R&D expense was $14.6 million versus $26.3 million, and G&A expense was $14.8 million versus $24.2 million. Cash and cash equivalents were $24.7 million at December 31, 2020, which management said should fund operations through top-line CF data and into the fourth quarter of 2021. Forward guidance: top-line ELX-02 CF data is expected in the first half of 2021.
Greg Williams emphasized that Eloxx is continuing to advance its ERSG library, but the immediate focus is completing the Phase II ELX-02 cystic fibrosis trials. He repeatedly framed the first-half 2021 data as a potential “major value inflection point” and said the company is “laser focused” on the program. His tone was optimistic but measured, pointing to safety progress, higher-dose escalation, new trial sites, orphan designation, and growing scientific interest as indicators of momentum.
Stephen MacDonald said Eloxx ended 2020 with $24.7 million in cash and cash equivalents, and management believes that cash should fund operations through the CF topline readout and into the fourth quarter of 2021. He highlighted a narrower quarterly and annual net loss, with reduced operating expenses driven mainly by lower headcount, salaries, clinical and preclinical research costs, and professional services. He also noted non-cash stock compensation of $1.3 million in the fourth quarter and $8.7 million for the full year, plus 40.157 million common shares outstanding at year-end.
Analysts focused on what would constitute success in CF and what the topline package will include. Greg Williams said a meaningful result would look like Orkambi- or Symdeko-like sweat chloride reductions, roughly in the five-millimole-per-liter range or better, and noted literature suggests sweat chloride can vary by about eight or nine millimoles per liter day to day, so sufficient patient numbers matter. He said the company has not yet disclosed exact enrollment or the full contents of the topline release, but plans to pool data across Europe, Israel, Australia, the U.S. and Canada, and expects a clearer dose response across the four doses being tested.
The bull case from this call is that ELX-02 is advancing with no drug-related serious adverse events reported so far and dose escalation already cleared to the highest cohort. Management believes the program could deliver a meaningful CF readout in the first half of 2021, with enough external support, expanded geography, and scientific validation to keep momentum going.
The main risk is that the whole story still hinges on a single near-term Phase II CF readout, and management did not provide enrollment details or the exact topline package. They also emphasized that sweat chloride has meaningful variability and that success likely requires a clinically significant threshold, so the data could be hard to interpret if the effect is modest or not clearly dose-responsive.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 9.0%
- Shares Outstanding
- 3.44M
- Float Shares
- 310.61K
of shares held by institutions
22 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ecor1 Capital, LLC | 400.00K | 0 |
| Siren, L.L.C. | 400.00K | 0 |
| Nantahala Capital Management, LLC | 400.00K | 0 |
| Samsara Biocapital, LLC | 400.00K | 0 |
| Aberdeen Group PLC | 400.00K | 0 |
| Stonepine Capital Management, LLC | 381.98K | ▼ 15.18K |
| Morgan Stanley | 202.63K | ▲ 201.09K |
| Vanguard Capital Management LLC | 78.68K | 0 |
| Geode Capital Management, LLC | 19.95K | ▲ 19.95K |
| Vanguard Fiduciary Trust Co | 13.67K | ▲ 3.07K |
| Ubs Group AG | 2.03K | ▲ 1.39K |
| Vanguard Global Advisers, LLC | 718 | 0 |
Held by 26 ETFs
Biggest fund positions in ELOX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 19, 26 | Germano Geno J | other | 13,587 |
| Oct 19, 26 | Germano Geno J | other | 0 |
| Jun 10, 26 | Domicilium Real Estate Fund III LP | other | 361,578 |
| Jun 10, 26 | Domicilium Real Estate Fund III LP | other | 361,578 |
| Jun 10, 26 | Domicilium Real Estate Fund III LP | other | 238,422 |
| Jun 10, 26 | Domicilium Real Estate Fund III LP | other | 238,422 |
| Jun 5, 26 | Domicilium Real Estate Fund III LP | other | 0 |
| Jun 5, 26 | Domicilium Real Estate Fund III LP | other | 0 |
| Jun 5, 26 | Domicilium Real Estate Fund III LP | other | 0 |
| Jun 5, 26 | Domicilium Real Estate Fund III LP | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ELOX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ELOX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation
prnewswire.com · Nov 18
Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
gurufocus.com · Nov 16
Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
prnewswire.com · Nov 16
Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
prnewswire.com · Nov 2
Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
prnewswire.com · Oct 29
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D.
prnewswire.com · Oct 20
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
prnewswire.com · Oct 19
This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga.com · Oct 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice
